Not logged inFutibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
Sootome, Hiroshi; Fujita, Hidenori; Ito, Kenjiro; Ochiiwa, Hiroaki; Fujioka, Yayoi; Ito, Kimihiro; Miura, Akihiro; Sagara, Takeshi; Ito, Satoru; Ohsawa, Hirokazu; Otsuki, Sachie; Funabashi, Kaoru; Yashiro, Masakazu; Matsuo, Kenichi; Yonekura, Kazuhiko; Hirai, Hiroshi .png)
Share.png)
SaveTAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion MutationsHasako, Shinichi; Terasaka, Miki; Abe, Naomi; Uno, Takao; Ohsawa, Hirokazu; Hashimoto, Akihiro; Fujita, Ryoto; Tanaka, Kenji; Okayama, Takashige; Wadhwa, Renu; Miyadera, Kazutaka; Aoyagi, Yoshimi; Yonekura, Kazuhiko; Matsuo, Kenichi Share Save MET/VEGFR/FMS signaling contributes prostate cancer-induced osteoclast differentiation and bone resorptionWatanabe, Kenta; Hirata, Michiko; Tomomi, Tsukasa; Matsumoto, Chiho; Fujita, Hidenori; Yamada, Yukari; Matsuo, Kenichi; Yonekura, Kazuhiko; Miyaura, Chisato; Inada, Masaki Share Save The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate CancerWatanabe, Kenta; Hirata, Michiko; Tominari, Tsukasa; Matsumoto, Chiho; Fujita, Hidenori; Yonekura, Kazuhiko; Murphy, Gillian; Nagase, Hideaki; Miyaura, Chisato; Inada, Masaki Share Save TAS-115, a novel and highly potent VEGFR/MET inhibitor, shows prominent antitumor efficacy by restoring HGF-mediated hypoxia-resistant phenotype in clear cell sarcomaFujita, Hidenori; Yamada, Yukari; Terasaka, Miki; Fujioka, Yayoi; Harada, Naomoto; Hashimoto, Akihiro; Miyadera, Kazutaka; Matsuo, Kenichi; Yonekura, Kazuhiko Share Save TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical ModelsOhkubo, Shuichi; Kodama, Yasuo; Muraoka, Hiromi; Hitotsumachi, Hiroko; Yoshimura, Chihoko; Kitade, Makoto; Hashimoto, Akihiro; Ito, Kenjiro; Gomori, Akira; Takahashi, Koichi; Shibata, Yoshihiro; Kanoh, Akira; Yonekura, Kazuhiko Share Save The Novel VEGF Receptor/MET-Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability ProfileFujita, Hidenori; Miyadera, Kazutaka; Kato, Masanori; Fujioka, Yayoi; Ochiiwa, Hiroaki; Huang, Jinhong; Ito, Kimihiro; Aoyagi, Yoshimi; Takenaka, Toru; Suzuki, Takamasa; Ito, Satoko; Hashimoto, Akihiro; Suefuji, Takashi; Egami, Kosuke; Kazuno, Hideki; Suda, Yoshimitsu; Nishio, Kazuto; Yonekura, Kazuhiko Share Save TAS-117, a highly selective non-ATP competitive inhibitor of AKT demonstrated antitumor activity in combination with chemotherapeutic agents and molecular targeted drugs.Ichikawa, Koji; Abe, Tetsuya; Nagase, Hideki; Saito, Hitoshi; Fujita, Ryouto; Okada, Megumu; Yonekura, Kazuhiko; Shimomura, Toshiyasu; Utsugi, Teruhiro Share Save TAS-116, an orally available HSP90a and 13 selective inhibitor, exhibits synergistic effects in combination with taxanes in EGFR-tyrosine kinase inhibitor-resistant human NSCLC xenograft models through the downregulation of key molecules involved in drug resistance of cancer chemotherapy.Muraoka, Hiromi; Kanoh, Akira; Hashimoto, Akihiro; Ito, Kenjiro; Suzuki, Takamasa; Takahashi, Kouichi; Yoshimura, Chihoko; Kitade, Makoto; Yonekura, Kazuhiko; Ohkubo, Shuichi; Utsugi, Teruhiro Share Save TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalitiesOchiiwa, Hiroaki; Fujita, Hidenori; Itoh, Kimihiro; Sootome, Hiroshi; Hashimoto, Akihiro; Fujioka, Yayoi; Nakatsuru, Yoko; Oda, Nobuyuki; Yonekura, Kazuhiko; Hirai, Hiroshi; Utsugi, Teruhiro Share Save In vitro characterization of TAS-121, a novel, highly potent, and mutant-specific EGFR-TKI.Ito, Kimihiro; Miyadera, Kazutaka; Aoyagi, Yoshimi; Kato, Masanori; Yonekura, Kazuhiko; Iwasawa, Yoshikazu; Utsugi, Teruhiro Share Save TAS-117, a highly potent and selective non-ATP competitive inhibitor of AKT, demonstrates a toxicity profile with manageable hyperglycemia in rats.Moriyama, Kenji; Yamaguchi, Masahiro; Sugimoto, Shigeo; Matsumura, Hirofumi; Ninomiya, Fumiko; Besshi, Kazuhiko; Morita, Fumio; Hayashi, Taiji; Fujita, Ryouto; Fukushima, Hiroto; Shimomura, Toshiyasu; Yonekura, Kazuhiko; Utsugi, Teruhiro Share Save TAS-116, an orally available HSP90α/β selective inhibitor: Synthesis and biological evaluation.Uno, Takao; Kitade, Makoto; Yamashita, Satoshi; Oshiumi, Hiromi; Kawai, Yuichi; Mizutani, Takashi; Yoshimura, Chihoko; Kodama, Yasuo; Muraoka, Hiromi; Takahashi, Kouichi; Yonekura, Kazuhiko; Ohkubo, Shuichi; Utsugi, Teruhiro Share Save TAS-116, an orally available HSP90α/β selective inhibitor, has potent antitumor activity in small cell lung cancer as a single agent and in combination with an anthracycline derivative, amrubicin.Muraoka, Hiromi; Yoshimura, Chihoko; Hashimoto, Akihiro; Ito, Kenjiro; Kitade, Makoto; Yonekura, Kazuhiko; Ohkubo, Shuichi; Utsugi, Teruhiro Share Save Characterization of TAS-121, a novel mutant-specific EGFR-TKI, on pharmacokinetics, pharmacodynamics, and antitumor activity.Kato, Masanori; Miyadera, Kazutaka; Shibata, Yoshihiro; Ito, Kimihiro; Aoyagi, Yoshimi; Chiba, Masato; Yonekura, Kazuhiko; Iwasawa, Yoshikazu; Utsugi, Teruhiro Share Save MET/VEGFR dual inhibition and prominent safety profile of TAS-115 are favorable for the combination with chemotherapeutic drugsFujita, Hidenori; Kato, Masanori; Fujioka, Yayoi; Sato, Tsudoi; Ochiiwa, Hiroaki; Huang, Jinhong; Ito, Kimihiro; Aoyagi, Yoshimi; Suzuki, Takamasa; Ito, Satoko; Ito, Kenjiro; Hashimoto, Akihiro; Nakaya, Yoko; Miyadera, Kazutaka; Yonekura, Kazuhiko Share Save TAS-115: a highly potent c-Met plus VEGFRs dual inhibitor with prominently safer profileFujita, Hidenori; Miyadera, Kazutaka; Ito, Kimihiro; Takenaka, Toru; Huang, Jinhong; Ito, Satoko; Suzuki, Takamasa; Ochiiwa, Hiroaki; Egami, Kousuke; Suefuji, Takashi; Sato, Ayako; Sato, Tsudoi; Fujioka, Yayoi; Katol, Masanori; Aoyagi, Yoshimi; Hashimoto, Akihiro; Kazuno, Hideki; Suda, Yoshimitsu; Yonekura, Kazuhiko Share Save The prominent safety profile of TAS-115, a novel c-Met plus VEGFR dual kinase inhibitor can lead to potentiate the efficacy via durable inhibition of angiogenesisOchiiwa, Hiroaki; Fujita, Hidenori; Ito, Kimihiro; Takenaka, Toru; Huang, Jinhong; Ito, Satoko; Suzuki, Takamasa; Egami, Kousuke; Suefuji, Takashi; Sato, Ayako; Sato, Tsudoi; Fujioka, Yayoi; Kato, Masanori; Aoyagi, Yoshimi; Hashimoto, Akihiro; Kazuno, Hideki; Miyadera, Kazutaka; Suda, Yoshimitsu; Yonekura, Kazuhiko Share Save Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
